Skip to content
DataLookout
Menu

PRECISE DM DXNCT07111416

Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis

StatusEnrolling by Invitation
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 8 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Apr 1, 2026 to Dec 1, 2026 Show 4 more changesShow less
    • Enrolling by invitation only
    • Start date changed from estimate of Sep 1, 2025 to Dec 1, 2025
    • Eligibility criteria expanded, about 18 words
    • Study completion pushed from May 1, 2026 to Mar 1, 2027
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Calculate the Mean Absolute Difference Between A1c-Derived Estimated Average Glucose (eAG) and CGM-Derived eAG
Timeframe: From 1 week after enrollment to the end of their enrollment at either week 5 or week 10

Sites

1 site in 1 country

  • Brigham and Women's HospitalBoston, Massachusetts, United States